Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: A double-blind placebo-controlled trial
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
The objective was to examine duloxetine 60-120 mg/day treatment for relapse prevention in adults with generalized anxiety disorder (GAD). Adult patients (N=887; mean age=43.3 years; 61.0% female) with DSM-IV-TR-defined GAD diagnosis were treated with duloxetine for 26 weeks. Patients who completed open-label phase and were treatment responders (>or=50% reduction in Hamilton Anxiety Rating Scale total score to <or=11 and "much"/"very much improved" ratings for the last 2 visits of open-label phase) were randomly assigned to receive duloxetine or placebo for a 26-week double-blind continuation phase. Relapse was defined as >or=2-point increase in illness severity ratings or by discontinuation due to lack of efficacy. During the double-blind phase, placebo-treated patients (N=201) relapsed more frequently (41.8%) than duloxetine-treated patients (13.7%, N=204, P<or=0.001) and worsened on each outcome measure (P<or=0.001, all comparisons). Duloxetine 60-120 mg/day treatment was efficacious and reduced risk of relapse in patients with GAD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Assessment of suicidal intention: The Scale for Suicide Ideation.
Beck, A. T., Kovacs, M., & Weissman, A. (1979) · Journal of Consulting and Clinical Psychology · doi:10.1037//0022-006x.47.2.343 · Cited by 3,419
Organizing Care for Patients with Chronic Illness
Wagner, E. H., Austin, B. T., & Korff, M. V. (1996) · The Milbank Quarterly · doi:10.2307/3350391 · Cited by 2,877
Size and burden of mental disorders in Europe—a critical review and appraisal of 27 studies
Wittchen, H.-U., & Jacobi, F. (2005) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.04.012 · Cited by 1,503
Assessing Psychiatric Impairment in Primary Care with the Sheehan Disability Scale
Leon, A. C., Olfson, M., Portera, L., Farber, L., & Sheehan, D. V. (1997) · The International Journal of Psychiatry in Medicine · doi:10.2190/t8em-c8yh-373n-1uwd · Cited by 987 · cited 1×
“The global functioning impairment score is the sum of the 3 items, and global scores N5 have been shown to indicate impairment associated with psychiatric illness (Leon et al., 1997).”
BackgroundBruce, S. E., Yonkers, K. A., Otto, M. W., Eisen, J. L., Weisberg, R. B., Pagano, M., Shea, M. T., & Keller, M. B. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.6.1179 · Cited by 963
Sareen, J., Cox, B. J., Afifi, T. O., de Graaf, R., Asmundson, G. J. G., ten Have, M., & Stein, M. B. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.11.1249 · Cited by 824
Shear, M. K., Vander Bilt, J., Rucci, P., Endicott, J., Lydiard, B., Otto, M. W., Pollack, M. H., Chandler, L., Williams, J., Ali, A., et al. (2001) · Depression and Anxiety · doi:10.1002/da.1033 · Cited by 483
Phenomenology and Course of Generalised Anxiety Disorder
Yonkers, K. A., Warshaw, M. G., Massion, A. O., & Keller, M. B. (1996) · British Journal of Psychiatry · doi:10.1192/bjp.168.3.308 · Cited by 242 · cited 1×
“After the onset of GAD, the course may fluctuate in severity of symptoms, but impairment associated with GAD tends to persist, and spontaneous remission is rare (Yonkers et al., 1996).”
Background
Research works printed but not linked: 25
- Acharya, 2007, Duloxetine: meta-analyses of suicidal behaviors and ideation in clinical trials for major depressive disorder, J. Clin. Psychopharmacol., 26, 587, 10.1097/01.jcp.0000246216.26400.db · DOI · Paper page
- Allgulander, 2006, Prevention of relapse in generalized anxiety disorder by escitalopram treatment, Int. J. Neuropsychopharmacol., 9, 495, 10.1017/S1461145705005973 · DOI · Paper page
- Allgulander, 2007, Pharmacotherapy for generalized anxiety disorder: results of duloxetine treatment from a pooled analysis of 3 clinical trials, Curr. Med. Res. Opin., 23, 1245, 10.1185/030079907X182202 · DOI · Paper page
- Beck, 1979, Assessment of suicidal ideation: the Scale for Suicidal Ideation, J. Consult. Clin. Psychol., 47, 343, 10.1037/0022-006X.47.2.343 · doi:10.1037/0022-006x.47.2.343 · Paper page
- Boden, 2007, Anxiety disorders and suicidal behaviors in adolescence and young adulthood: findings from a longitudinal study, Psychol. Med., 37, 431, 10.1017/S0033291706009147 · DOI · Paper page
- Endicott, 1993, Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure, Psychopharmacol. Bull., 29, 321
- EuroQol Group, 1990, EuroQol: a new facility for the measurement of health-related quality of life, Health Policy, 16, 199, 10.1016/0168-8510(90)90421-9 · DOI · Paper page
- Gelenberg, 2000, Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial, JAMA, 283, 3082, 10.1001/jama.283.23.3082 · DOI · Paper page
- Goodman, 2004, Selecting pharmacotherapy for generalized anxiety disorder, J. Clin. Psychiatry, 65, 8
- Hamilton, 1959, The assessment of anxiety states by rating, Br. J. Med. Psychol., 32, 50, 10.1111/j.2044-8341.1959.tb00467.x · DOI · Paper page
- Hartford, 2007, Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial, Int. Clin. Psychopharmacol., 22, 167, 10.1097/YIC.0b013e32807fb1b2 · DOI · Paper page
- Keller, 2002, Raising the expectations of long-term treatment strategies in anxiety disorders, Psychopharmacol. Bull., 36, 166
- Koponen, 2007, Efficacy of duloxetine for treatment of generalized anxiety disorder: implications for primary care physicians, Prim. Care Companion J. Clin. Psychiat., 9, 100
- Lipman, 1976, Outpatient treatment of neurotic depression: medication and group psychotherapy, Proc. Annu. Meet. Am. Psychopathol. Assoc., 64, 178
- Mahe, 2000, Long-term pharmacological treatment of generalized anxiety disorder, Int. Clin. Psychopharmacol., 15, 99, 10.1097/00004850-200015020-00006 · DOI · Paper page
- McManus, 2004, Length of therapy with selective serotonin reuptake inhibitors and tricyclic antidepressants in Australia, Aust. N. Z. J. Psychiatry, 38, 450, 10.1080/j.1440-1614.2004.01383.x · DOI
- Raskin, 1969, Replication of factors of psychopathology in interview, ward behavior and self-report ratings of hospitalized depressives, J. Nerv. Ment. Dis., 148, 87, 10.1097/00005053-196901000-00010 · DOI · Paper page
- Rynn, 2008, Efficacy and safety of duloxetine in treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial, Depress. Anxiety, 25, 182, 10.1002/da.20271 · DOI · Paper page
- Sheehan, 1998, The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10, J. Clin. Psychiatry, 59, 22
- Sokero, 2003, Suicidal ideation and attempts among psychiatric patients with major depressive disorder, J. Clin. Psychiatry, 64, 1094, 10.4088/JCP.v64n0916 · DOI · Paper page
- Stein, 2006, Antidepressant adherence and medical resource use among managed care patients with anxiety disorders, Psychiatric Serv., 57, 673, 10.1176/ps.2006.57.5.673 · doi:10.1176/ps.2006.57.5.673 · Paper page
- Stocchi, 2003, Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder, J. Clin. Psychiatry, 64, 250, 10.4088/JCP.v64n0305 · DOI · Paper page
- Thase, 2005, Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine, J. Clin. Psychopharmacol., 25, 132, 10.1097/01.jcp.0000155815.44338.95 · DOI · Paper page
- Wittchen, 2001, Generalized anxiety disorder: nature and course, J. Clin. Psychiatry, 62, 15
- Zigmond, 1983, The Hospital Anxiety and Depression Scale, Acta Psychiatr. Scand., 67, 361, 10.1111/j.1600-0447.1983.tb09716.x · DOI · Paper page
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“In RCT discontinuation studies, duloxetine [624], esci-”
Treatment of anxiety disorders
Bandelow, B., Michaelis, S., & Wedekind, D. (2017) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2017.19.2/bbandelow · Cited by 811
DeMartini, J., Patel, G., & Fancher, T. L. (2019) · Annals of Internal Medicine · doi:10.7326/aitc201904020 · Cited by 226
Strawn, J. R., Geracioti, L., Rajdev, N., Clemenza, K., & Levine, A. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1491966 · Cited by 214
Mao, J. J., Xie, S. X., Keefe, J. R., Soeller, I., Li, Q. S., & Amsterdam, J. D. (2016) · Phytomedicine · doi:10.1016/j.phymed.2016.10.012 · Cited by 161
“(Allgulander et al., 2006; Davidson et al., 2008; Gelenberg et al., 2000; Rickels et al., 2010; Stocchi et al., 2003), with some exceptions (Montgomery et al., 2002; Stein et al., 2012).”
Metadata
- Authors
- Davidson, J. R. T., Wittchen, H.-U., Llorca, P.-M., Erickson, J., Detke, M., Ball, S. G., & Russell, J. M.
- Venue
- European Neuropsychopharmacology
- Publisher
- Elsevier BV
- Published
- 2008-09
- Volume
- 18
- Issue
- 9
- Pages
- 673-681
- ISSN
- 0924-977X (ISSN-L)
- OpenAlex
- W2010388663
- Cited by
- 68
- References
- 8
- FWCI
- 11.29
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: A double-blind placebo-controlled trial. https://app.cochat.ai/papers/10.1016/j.euroneuro.2008.05.002
- The paper
- Davidson, J. R. T., Wittchen, H.-U., Llorca, P.-M., Erickson, J., Detke, M., Ball, S. G., & Russell, J. M. (2008). Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: A double-blind placebo-controlled trial. European Neuropsychopharmacology. https://doi.org/10.1016/j.euroneuro.2008.05.002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.